Developer docs
API playgroundTry for free, no card

Search company profiles

Eilean Therapeutics

Full company profile

uuid00085xu

Namestring
Eilean Therapeutics
Legal namestring
Eilean Therapeutics Inc.
Websiteurl
eileanther.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Eilean Therapeutics is a privately held, clinical-stage small molecule oncology drug discovery company founded in 2022 and headquartered in Dover, Delaware, with a wholly-owned Australian subsidiary (Eilean Therapeutics AU Pty Ltd) used for first-in-human Phase 1 dosing via the Australian HREC/TGA CTN pathway. The company is developing pan-variant therapies that target escape mutations and resistance mechanisms in hematologic malignancies and solid tumors, with the stated objective of overcoming the limitations of current oncology therapeutics. Its pipeline spans JAK2 V617F (ZE74-0282 for myelofibrosis), FLT3-mutated AML (lomonitinib), BCL2-driven CLL/AML (eiletoclax), menin-KMT2A AML (balamenib), MALT1 degradation for ulcerative colitis (TE205), brain-penetrant CDK2/CDK4, pan-EGFR, PTPN2/PTPN1 (acquired via Ness Therapeutics), c-MET, pan-KRAS, KRAS G12D, and BTK programs. Lomonitinib was selected for a new arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial and received FDA IND clearance in 2024.

The company's discovery engine is a proprietary hybrid AI/ML drug design platform that leverages Expert Systems Inc. technology and partner proprietary data to accelerate rational design, with demonstrated selectivity outcomes including >500-fold JAK2 V617F JH2 versus WT selectivity, picomolar JAK2 V617F potency, and >1000-fold PTPN2/PTPN1 selectivity over other phosphatases. The portfolio includes multiple modalities — selective kinase inhibitors, molecular degraders, covalent and reversible binders, and protein-protein interaction inhibitors — designed for combination potential.

Eilean is pre-revenue, with no commercialized products and pricing not publicly disclosed. The intended revenue model is eventual drug commercialization and licensing, supported by clinical development co-funding through partnerships such as the LLS Beat AML Master Clinical Trial. The company is co-founded by OrbiMed, Torrey Pines Investment, and Dr. John C. Byrd (Chairman of UC Department of Internal Medicine, serving as Interim Chief Medical Officer), with a full C-suite development team (CEO Iain Dukes, CSO Amy Burd, COO Nikolay Savchuk, CDO Brian Ledwith, Head of CMC Fraser Pickersgill) for a company of 11–50 employees.

Short descriptiontext

Eilean Therapeutics is a privately held, clinical-stage small molecule oncology drug discovery company founded in 2022, developing pan-variant therapies that target escape mutations and resistance mechanisms in hematologic malignancies and solid tumors, supported by a proprietary hybrid AI/ML drug design platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDover, United States
HQ citystring
Dover
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug discovery, small molecule therapeutics, kinase inhibitor development, hematologic cancer therapies, targeted cancer treatments
Industry4 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Eilean Therapeutics is a pre-revenue biopharmaceutical company focused on discovering and developing small molecule therapies. Revenue will be generated through eventual commercialization of drug candidates upon successful clinical development and regulatory approvals. The company develops proprietary therapeutics targeting genetic vulnerabilities in hematologic malignancies and solid tumors.

eileanther.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eilean Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule targeted therapies for hematologic malignancies and solid tumors. Its pipeline includes selective kinase inhibitors, protein degraders, and immuno-oncology agents designed to overcome resistance mechanisms in cancers such as AML, CLL, NSCLC, and inflammatory bowel disease. The company leverages a proprietary hybrid AI/ML drug design platform to rationally design first-in-class and best-in-class oncology drug candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • >500-fold selectivity for JAK2 V617F JH2 versus WT JAK2 JH2 in cellular assays
+4 more records
Product overview1 text field

Eilean Therapeutics is a small molecule oncology drug discovery company developing a diversified pipeline of targeted cancer therapies. The company's portfolio includes both hematologic malignancy programs (ZE74-0282 for JAK2-driven myeloproliferative neoplasms, lomonitinib for FLT3-mutated AML, eiletoclax for BCL2-driven cancers, balamenib for menin-driven AML, MALT1 degrader for B-cell malignancies) and solid tumor programs (brain-penetrant CDK2/CDK4 inhibitors, pan-EGFR inhibitor, c-MET inhibitor, pan-KRAS molecular glue, KRAS G12D inhibitor). The company also acquired a PTPN2 inhibitor program for immuno-oncology. Programs span discovery through Phase 1 clinical stages, with several having received regulatory clearance for human trials.

Product and service13 records
1Lomonitinib (ZE46-0134)
CategoryDrug candidate (small molecule kinase inhibitor)
Description

Highly potent and selective pan-FLT3/IRAK4 inhibitor targeting clinically relevant FLT3 mutations including the gatekeeper mutation, as well as putative escape pathways in relapsed/refractory AML. FDA IND-cleared for U.S. Phase 1 trial.

2Eiletoclax (ZE50-0134)
CategoryDrug candidate (small molecule BCL2 inhibitor)
Description

Highly potent and selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax, for treatment of AML and CLL. Phase 1 trial initiated in Australia.

3Balamenib (ZE63-0302)
CategoryDrug candidate (small molecule menin-KMT2A inhibitor)
Description

Selective best-in-class oral small molecule inhibitor of the menin-KMT2A interaction for treatment of AML, with improved safety profile including absence of QTc prolongation.

4ZE74-0282
CategoryDrug candidate (small molecule kinase inhibitor)
Description

Highly selective JAK2 V617F inhibitor targeting the JH2 pseudokinase domain of mutant JAK2, developed as a once-daily oral therapy for myeloproliferative neoplasms including myelofibrosis and polycythemia vera. Demonstrates >500-fold selectivity for mutant over wild-type JAK2.

5TE205 (MALT1 Degrader)
CategoryDrug candidate (targeted protein degrader)
Description

First-in-class oral MALT1 degrader demonstrating in vivo efficacy as a disease-modifying therapy for ulcerative colitis and B-cell malignancies. Selectively degrades MALT1 to suppress NF-κB signaling and restore intestinal integrity.

6PTPN2 Inhibitor
7CDK2 Inhibitor
CategoryDrug candidate (small molecule kinase inhibitor)
Description

Selective, brain-penetrant CDK2 inhibitor for treatment of CCNE1-amplified cancers and aggressive solid tumors. Demonstrates high selectivity for CDK2 over other cyclin-dependent kinases with broad therapeutic window.

8CDK4 Inhibitor
9Pan-EGFR Inhibitor (ZE77-0273)
CategoryDrug candidate (small molecule kinase inhibitor)
Description

Reversible, brain- and lung-permeable pan-EGFR inhibitor demonstrating broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC) with high selectivity index versus wild-type EGFR.

10c-MET Inhibitor
11Pan-KRAS Molecular Glue
12KRAS G12D Inhibitor
13BTK Inhibitor
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1The Leukemia & Lymphoma Society (LLS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-11
Description

Eilean Therapeutics joined The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial, a groundbreaking collaborative targeted treatment approach. Eilean's lomonitinib was selected for a new trial arm for patients with FLT3 mutated relapsed/refractory AML. Beat AML is among the first cancer clinical trials sponsored by a nonprofit, bringing together clinicians, cancer centers, pharmaceutical companies, and operational partners.

eileanther.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-04
Description

Eilean Therapeutics acquired Ness Therapeutics Inc in an all-equity transaction to obtain best-in-class PTPN2 inhibitors providing immuno-oncological therapy with improved safety and tolerability profile. Ness' lead molecules demonstrate sub-nanomolar PTPN2/PTPN1 inhibitory activity and outstanding >1000-fold selectivity against all other phosphatases.

Strategic tierCoreTypeTechnology or Integration
Description

Eilean Therapeutics utilizes a proprietary hybrid AI platform of Expert Systems Inc., leveraging key partners' proprietary data, chem/bio tools, knowledge and expertise to choose highly valuable molecular mechanisms of pathology, rationally design, accelerate discovery and optimize development of best-in-class and first-in-class therapies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Eilean's PTPN2 inhibitor program is partnered with Mondego Bio, a Portuguese startup developing cancer immunotherapy treatments. The collaboration involves drug discovery, scale-up manufacturing, and accelerating clinical readiness, supported by ChemDiv's and Mondego's facilities across Europe and the U.S.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops revumenib (FDA-approved menin inhibitor) for KMT2A-rearranged AML — the lead competing asset to Eilean's balamenib in the menin-KMT2A space with established commercial validation.

TypeDirect peer
Description

Clinical-stage small molecule company focused on hematologic diseases with multiple programs in early-stage trials — similar team size, capital profile, and hematology-focused pipeline breadth as Eilean.

TypeBroad incumbent
Description

Established small molecule oncology company with approved kinase inhibitors (AYVAKIT) targeting hematologic malignancies and solid tumors — represents the scaled commercial endpoint for Eilean's kinase-inhibitor pipeline strategy.

TypeDirect peer
Description

Clinical-stage hematology company developing telomerase inhibitor (Rytelo) for myeloid hematologic malignancies — comparable late-stage clinical profile in genetically-defined hematology indications.

TypeDirect peer
Description

Was a small molecule oncology company developing KRAS inhibitors (KRAZATI) acquired by Bristol Myers Squibb — directly comparable for Eilean's pan-KRAS molecular glue and KRAS G12D programs and demonstrates large-pharma M&A appetite for differentiated KRAS assets.

TypeDirect peer
Description

Clinical-stage small molecule oncology company developing menin inhibitors (ziftomenib) for AML — directly comparable to Eilean's balamenib program. Both target genetically-defined AML populations and compete for similar clinical/partnering opportunities.

7Forma Therapeutics
TypeDirect peer
Description

Was a clinical-stage small molecule company focused on hematologic malignancies and rare cancers (acquired by Novo Nordisk for $1.1B) — direct comparable for Eilean's hematology pipeline and demonstrates M&A exit path.

TypeEmerging player
Description

Clinical-stage biotech using a proprietary gene regulatory platform to develop small molecule oncology therapies — analogous platform-driven discovery model to Eilean's AI/ML approach with similar pipeline breadth.

TypeBroad incumbent
Description

Major hematology/oncology company with JAKAFI (ruxolitinib) — the incumbent JAK2 inhibitor against which Eilean's wild-type-sparing ZE74-0282 must differentiate for myelofibrosis/polycythemia vera market share.

10Rigel Pharmaceuticals
TypeDirect peer
Description

Small molecule hematology/oncology company with approved kinase inhibitors and pipeline targeting hematologic malignancies — comparable business model, therapeutic focus, and small-cap clinical-stage profile to Eilean.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eilean Therapeutics

Oncology Pharmaceuticalseileanther.com

Eilean Therapeutics is a privately held, clinical-stage small molecule oncology drug discovery company founded in 2022, developing pan-variant therapies that target escape mutations and resistance mechanisms in hematologic malignancies and solid tumors, supported by a proprietary hybrid AI/ML drug design platform.

What Eilean Therapeutics does

Eilean Therapeutics is a privately held, clinical-stage small molecule oncology drug discovery company founded in 2022 and headquartered in Dover, Delaware, with a wholly-owned Australian subsidiary (Eilean Therapeutics AU Pty Ltd) used for first-in-human Phase 1 dosing via the Australian HREC/TGA CTN pathway. The company is developing pan-variant therapies that target escape mutations and resistance mechanisms in hematologic malignancies and solid tumors, with the stated objective of overcoming the limitations of current oncology therapeutics. Its pipeline spans JAK2 V617F (ZE74-0282 for myelofibrosis), FLT3-mutated AML (lomonitinib), BCL2-driven CLL/AML (eiletoclax), menin-KMT2A AML (balamenib), MALT1 degradation for ulcerative colitis (TE205), brain-penetrant CDK2/CDK4, pan-EGFR, PTPN2/PTPN1 (acquired via Ness Therapeutics), c-MET, pan-KRAS, KRAS G12D, and BTK programs. Lomonitinib was selected for a new arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial and received FDA IND clearance in 2024.

The company's discovery engine is a proprietary hybrid AI/ML drug design platform that leverages Expert Systems Inc. technology and partner proprietary data to accelerate rational design, with demonstrated selectivity outcomes including >500-fold JAK2 V617F JH2 versus WT selectivity, picomolar JAK2 V617F potency, and >1000-fold PTPN2/PTPN1 selectivity over other phosphatases. The portfolio includes multiple modalities — selective kinase inhibitors, molecular degraders, covalent and reversible binders, and protein-protein interaction inhibitors — designed for combination potential.

Eilean is pre-revenue, with no commercialized products and pricing not publicly disclosed. The intended revenue model is eventual drug commercialization and licensing, supported by clinical development co-funding through partnerships such as the LLS Beat AML Master Clinical Trial. The company is co-founded by OrbiMed, Torrey Pines Investment, and Dr. John C. Byrd (Chairman of UC Department of Internal Medicine, serving as Interim Chief Medical Officer), with a full C-suite development team (CEO Iain Dukes, CSO Amy Burd, COO Nikolay Savchuk, CDO Brian Ledwith, Head of CMC Fraser Pickersgill) for a company of 11–50 employees.

Eilean Therapeutics firmographics

Firmographics
Name
Eilean Therapeutics
Legal name
Eilean Therapeutics Inc.
Website
https://eileanther.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Eilean Therapeutics is a privately held, clinical-stage small molecule oncology drug discovery company founded in 2022, developing pan-variant therapies that target escape mutations and resistance mechanisms in hematologic malignancies and solid tumors, supported by a proprietary hybrid AI/ML drug design platform.
Ownership category
akta.pro rank

Eilean Therapeutics industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Oncology drug discovery
  • Small molecule therapeutics
  • Kinase inhibitor development
  • Hematologic cancer therapies
  • Targeted cancer treatments

Where Eilean Therapeutics is headquartered

Location

Headquarters

HQ city
Dover
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Eilean Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Eilean Therapeutics is a pre-revenue biopharmaceutical company focused on discovering and developing small molecule therapies. Revenue will be generated through eventual commercialization of drug candidates upon successful clinical development and regulatory approvals. The company develops proprietary therapeutics targeting genetic vulnerabilities in hematologic malignancies and solid tumors.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Eilean Therapeutics product offering

Product offering

Core offering

Eilean Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule targeted therapies for hematologic malignancies and solid tumors. Its pipeline includes selective kinase inhibitors, protein degraders, and immuno-oncology agents designed to overcome resistance mechanisms in cancers such as AML, CLL, NSCLC, and inflammatory bowel disease. The company leverages a proprietary hybrid AI/ML drug design platform to rationally design first-in-class and best-in-class oncology drug candidates.

Product overview

Eilean Therapeutics is a small molecule oncology drug discovery company developing a diversified pipeline of targeted cancer therapies. The company's portfolio includes both hematologic malignancy programs (ZE74-0282 for JAK2-driven myeloproliferative neoplasms, lomonitinib for FLT3-mutated AML, eiletoclax for BCL2-driven cancers, balamenib for menin-driven AML, MALT1 degrader for B-cell malignancies) and solid tumor programs (brain-penetrant CDK2/CDK4 inhibitors, pan-EGFR inhibitor, c-MET inhibitor, pan-KRAS molecular glue, KRAS G12D inhibitor). The company also acquired a PTPN2 inhibitor program for immuno-oncology. Programs span discovery through Phase 1 clinical stages, with several having received regulatory clearance for human trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lomonitinib (ZE46-0134) Highly potent and selective pan-FLT3/IRAK4 inhibitor targeting clinically relevant FLT3 mutations including the gatekeeper mutation, as well as putative escape pathways in relapsed/refractory AML. FDA IND-cleared for U.S. Phase 1 trial.
  • Eiletoclax (ZE50-0134) Highly potent and selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax, for treatment of AML and CLL. Phase 1 trial initiated in Australia.
  • Balamenib (ZE63-0302) Selective best-in-class oral small molecule inhibitor of the menin-KMT2A interaction for treatment of AML, with improved safety profile including absence of QTc prolongation.
  • ZE74-0282 Highly selective JAK2 V617F inhibitor targeting the JH2 pseudokinase domain of mutant JAK2, developed as a once-daily oral therapy for myeloproliferative neoplasms including myelofibrosis and polycythemia vera. Demonstrates >500-fold selectivity for mutant over wild-type JAK2.
  • TE205 (MALT1 Degrader) First-in-class oral MALT1 degrader demonstrating in vivo efficacy as a disease-modifying therapy for ulcerative colitis and B-cell malignancies. Selectively degrades MALT1 to suppress NF-κB signaling and restore intestinal integrity.
  • PTPN2 Inhibitor
  • CDK2 Inhibitor Selective, brain-penetrant CDK2 inhibitor for treatment of CCNE1-amplified cancers and aggressive solid tumors. Demonstrates high selectivity for CDK2 over other cyclin-dependent kinases with broad therapeutic window.
  • CDK4 Inhibitor
  • Pan-EGFR Inhibitor (ZE77-0273) Reversible, brain- and lung-permeable pan-EGFR inhibitor demonstrating broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC) with high selectivity index versus wild-type EGFR.
  • c-MET Inhibitor
  • Pan-KRAS Molecular Glue
  • KRAS G12D Inhibitor
  • BTK Inhibitor

Quantifiable outcome

  • >500-fold selectivity for JAK2 V617F JH2 versus WT JAK2 JH2 in cellular assays
  • +4 more outcomes

Companies that use Eilean Therapeutics

Customer profile

Segments5 records

Ideal customer profiles2 records

Eilean Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Eilean Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • The Leukemia & Lymphoma Society (LLS)coreStrategic or Co-development Partner · 11 June 2024Eilean Therapeutics joined The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial, a groundbreaking collaborative targeted treatment approach. Eilean's lomonitinib was selected for a new trial arm for patients with FLT3 mutated relapsed/refractory AML. Beat AML is among the first cancer clinical trials sponsored by a nonprofit, bringing together clinicians, cancer centers, pharmaceutical companies, and operational partners.
  • Ness Therapeutics Inc (Ness)coreStrategic or Co-development Partner · 4 March 2024Eilean Therapeutics acquired Ness Therapeutics Inc in an all-equity transaction to obtain best-in-class PTPN2 inhibitors providing immuno-oncological therapy with improved safety and tolerability profile. Ness' lead molecules demonstrate sub-nanomolar PTPN2/PTPN1 inhibitory activity and outstanding >1000-fold selectivity against all other phosphatases.
  • Expert Systems Inc.coreTechnology or IntegrationEilean Therapeutics utilizes a proprietary hybrid AI platform of Expert Systems Inc., leveraging key partners' proprietary data, chem/bio tools, knowledge and expertise to choose highly valuable molecular mechanisms of pathology, rationally design, accelerate discovery and optimize development of best-in-class and first-in-class therapies.
  • Mondego BiominorStrategic or Co-development PartnerEilean's PTPN2 inhibitor program is partnered with Mondego Bio, a Portuguese startup developing cancer immunotherapy treatments. The collaboration involves drug discovery, scale-up manufacturing, and accelerating clinical readiness, supported by ChemDiv's and Mondego's facilities across Europe and the U.S.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Eilean Therapeutics competitors and assessment

Company assessment

Direct peers

  • Syndax Pharmaceuticals: Develops revumenib (FDA-approved menin inhibitor) for KMT2A-rearranged AML — the lead competing asset to Eilean's balamenib in the menin-KMT2A space with established commercial validation.
  • Disc Medicine: Clinical-stage small molecule company focused on hematologic diseases with multiple programs in early-stage trials — similar team size, capital profile, and hematology-focused pipeline breadth as Eilean.
  • Geron Corporation: Clinical-stage hematology company developing telomerase inhibitor (Rytelo) for myeloid hematologic malignancies — comparable late-stage clinical profile in genetically-defined hematology indications.
  • Mirati Therapeutics: Was a small molecule oncology company developing KRAS inhibitors (KRAZATI) acquired by Bristol Myers Squibb — directly comparable for Eilean's pan-KRAS molecular glue and KRAS G12D programs and demonstrates large-pharma M&A appetite for differentiated KRAS assets.
  • Kura Oncology: Clinical-stage small molecule oncology company developing menin inhibitors (ziftomenib) for AML — directly comparable to Eilean's balamenib program. Both target genetically-defined AML populations and compete for similar clinical/partnering opportunities.
  • Forma Therapeutics: Was a clinical-stage small molecule company focused on hematologic malignancies and rare cancers (acquired by Novo Nordisk for $1.1B) — direct comparable for Eilean's hematology pipeline and demonstrates M&A exit path.
  • Rigel Pharmaceuticals: Small molecule hematology/oncology company with approved kinase inhibitors and pipeline targeting hematologic malignancies — comparable business model, therapeutic focus, and small-cap clinical-stage profile to Eilean.

Broad incumbents

  • Blueprint Medicines: Established small molecule oncology company with approved kinase inhibitors (AYVAKIT) targeting hematologic malignancies and solid tumors — represents the scaled commercial endpoint for Eilean's kinase-inhibitor pipeline strategy.
  • Incyte Corporation: Major hematology/oncology company with JAKAFI (ruxolitinib) — the incumbent JAK2 inhibitor against which Eilean's wild-type-sparing ZE74-0282 must differentiate for myelofibrosis/polycythemia vera market share.

Emerging players

  • Foghorn Therapeutics: Clinical-stage biotech using a proprietary gene regulatory platform to develop small molecule oncology therapies — analogous platform-driven discovery model to Eilean's AI/ML approach with similar pipeline breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Eilean Therapeutics social profiles

Digital presence

Eilean Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eilean Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Eilean Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Eilean Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eilean Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eilean Therapeutics

What does Eilean Therapeutics do?

Eilean Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule targeted therapies for hematologic malignancies and solid tumors. Its pipeline includes selective kinase inhibitors, protein degraders, and immuno-oncology agents designed to overcome resistance mechanisms in cancers such as AML, CLL, NSCLC, and inflammatory bowel disease. The company leverages a proprietary hybrid AI/ML drug design platform to rationally design first-in-class and best-in-class oncology drug candidates.

Is Eilean Therapeutics a public or private company?

Eilean Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eilean Therapeutics founded?

Eilean Therapeutics was founded in 2022. It employs 1 to 10 people.

Where is Eilean Therapeutics based?

Eilean Therapeutics is headquartered in Dover, United States, in the North America region.

How does Eilean Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Eilean Therapeutics's main competitors?

Direct peers on record are Syndax Pharmaceuticals, Disc Medicine, Geron Corporation, Mirati Therapeutics, Kura Oncology, Forma Therapeutics and Rigel Pharmaceuticals. Broad incumbents are Blueprint Medicines and Incyte Corporation. Foghorn Therapeutics is listed as an emerging player.

Does Eilean Therapeutics have an API?

No public API is recorded for Eilean Therapeutics.

What industry is Eilean Therapeutics in?

Eilean Therapeutics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireComprehensive Myelofibrosis Pipeline Overview: Insights into 50+ Companies and 55+ Drugs by 2026ResearchAndMarkets.com published the "Myelofibrosis - Pipeline Insight, 2026" report, providing an overview of the myelofibrosis drug development landscape covering over 50 companies and 55 pipeline drugs across clinical and pre-clinical stages. The report highlights key drugs in development including Ropeginterferon alfa-2b (Phase III, PharmaEssentia), Roginolisib (Phase II, iOnctura), RVU120 (Phase II, Ryvu Therapeutics), and PRT12396 (Phase I, Prelude Therapeutics). Notable developers in the space include Incyte Corporation and Takeda alongside emerging players such as Cellenkos, Ajax Therapeutics, Eilean Therapeutics, and Disc Medicine.BioSpaceEilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical DevelopmentEilean Therapeutics has advanced ZE74-0282, a highly selective inhibitor of the mutated JAK2 V617F variant, into first-in-human clinical development for myeloproliferative neoplasms including myelofibrosis. The drug demonstrated up to 500-fold selectivity for the mutated JAK2 over wild-type JAK2 and showed superior mutant selectivity compared to ruxolitinib in patient-derived whole blood assays. The company has submitted an IND application and plans to begin enrollment in a single ascending dose trial in healthy volunteers in Q1 2026, with subsequent studies planned in myelofibrosis patients.PR NewswireEilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical DevelopmentEilean Therapeutics has advanced its drug candidate ZE74-0282 into first-in-human clinical development for treating myeloproliferative neoplasms. The company submitted an Investigational New Drug application, with the initial single ascending dose trial in healthy volunteers planned to begin in the first quarter of 2026.PR NewswireEilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025Eilean Therapeutics LLC announced it will present preclinical data for its first-in-class, wild-type-sparing JAK2-JH2/V617F inhibitor ZE74-0282 at the 67th American Society of Hematology Annual Meeting, with first-in-human clinical studies planned to begin in December 2025. The drug demonstrated picomolar potency and over 500-fold selectivity for mutant JAK2 V617F versus wild-type JAK2 in cellular assays, along with favorable pharmacokinetics and toxicology profiles supporting a broad therapeutic window. ZE74-0282 represents a potential disease-modifying therapy for JAK2 V617F-driven myeloproliferative neoplasms, offering a differentiated mechanism compared to existing JH1-directed inhibitors like ruxolitinib and fedratinib.PR NewswireEilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and ImmunologyEilean Therapeutics presented preclinical in vivo data for TE205, its first-in-class MALT1 degrader, as a disease-modifying therapy for ulcerative colitis at the 4th International Conference on Microbiology and Immunology in Las Vegas. In DSS-induced colitis models, TE205 demonstrated structural and functional restoration of intestinal integrity by suppressing NF-κB signaling, rebalancing T-cell and macrophage populations, and restoring epithelial barrier function. The results establish TE205 as a potent candidate with disease-modifying potential for inflammatory bowel disease.PR NewswireEilean Therapeutics Presents Novel, Selective, Brain-Permeable CDK2 Inhibitor for Treatment of CCNE1-Dependent CancersEilean Therapeutics presented preclinical data for its novel, brain-permeable CDK2 inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The compound demonstrates high selectivity for CDK2 over other cyclin-dependent kinases with a broad therapeutic window in CCNE1-dependent cancer models that respond poorly to current standard-of-care treatments. The company plans to advance the candidate into a First-in-Human clinical study in Q4 2025.PR NewswireEiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International CoEilean Therapeutics announced the presentation of data for its pan-EGFR inhibitor candidate ZE77-0273, a reversible small-molecule drug targeting resistance mutations in EGFR-mutant non-small cell lung cancer. The drug candidate demonstrated broad activity against resistance mutations, high selectivity for mutant over wild-type EGFR, and a wide therapeutic window with favorable safety and tolerability profiles. The company is focused on developing small molecule inhibitors targeting escape mutations in hematologic malignancies and solid tumors using its proprietary hybrid AI/ML drug design platform.PR NewswireBiovance Capital leads Series A Financing in Mondego Bio together with OrbiMed and Torrey PinesBiovance Capital, OrbiMed, and Torrey Pines led a Series A financing for Portuguese startup Mondego Bio, which develops PTPN2 inhibitors for immuno-oncology. The round marks Biovance Capital Fund I's first investment, with the lead programs based on research from Eilean Therapeutics.YahooShaping the future of clinical trials in the EUThe 15th Annual OCT Europe conference will be held in Barcelona on 29-30 April, bringing together healthcare companies, CROs, and patient groups to discuss clinical trial operations. Keynote speakers include Jose Angel Aibar and industry leaders from AstraZeneca, ICON, and Eilean Therapeutics, with sessions on AI, eConsent, and patient centricity.